Ex-As­traZeneca ex­ec Lisa An­son to lead do-over at Redx; Ad­vax­is shakes up C-suite

→ Redx $REDX has en­list­ed es­teemed British ex­ec Lisa An­son to lead the com­pa­ny’s do-over as its CEO. Hav­ing held man­age­ment roles at As­traZeneca for 20 years — serv­ing as As­traZeneca UK’s pres­i­dent for the last six — An­son, who’s al­so the pres­i­dent of the As­so­ci­a­tion of the British Phar­ma­ceu­ti­cal In­dus­try, in­spires con­fi­dence about turn­ing things around for the bat­tered biotech. If the hopes are high, so are the stakes. Redx saw its shares sus­pend­ed al­most a year ago af­ter the city of Liv­er­pool said it went delin­quent on a £2 mil­lion loan, and was hit by a safe­ty cri­sis just last month that forced it to halt a PhI/II tri­al. An­son, how­ev­er, is up­beat about the work cut out for her: “The team have im­pressed me and the com­pa­ny now has a clear fo­cus on some very ex­cit­ing ar­eas of sci­ence in both fi­bro­sis and can­cer where there are a num­ber of on­go­ing pro­grams.” When she comes on the job on June 1, ex­ec­u­tive chair­man Iain Ross will re­vert to a non-ex­ec­u­tive po­si­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER